Precisio Biotix Therapeutics (“Precisio”) is a US-incorporated
industry leader in precision antibacterial biological solutions;
specifically, the identification and development of lysin, amurin, and phage solutions and related delivery technologies to combat
bacterial infections and address related unmet medical needs.
Precisio is a platform-plus-product drug discovery and
development company, with both Rx and consumer products. Precisio can provide low-cost antibacterials for most of the world.
Treating multiple bacterial conditions utilizing first-or best-in-class lysins with an emphasis on lung, vaginal, and topical treatments.
>More
Preventing and treating AMR resistant topical infections utilizing novel sustained-release phage spray and patch systems.
Lead product is for the treatment and prevention of topical AMR pressure injury infections.
>More
Antibiotic Resistance - The Need for New Treatments
According to WHO, if we do not take significant action, we will enter a post-antibiotic era in which a common infection and minor injury can be life-threatening. It is estimated that by 2050 more people will die from infection than from cancer.
>More
Contact Us
Precisio Biotix Therapeutics
Email to Director of Investor Relations: shencj@precisiobiotix.com
